Medications for Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome).
Found 1 Approved Drug for Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Vimizim
Generic Name
Elosulfase
Vimizim
Generic Name
Elosulfase
Form: Injection
Method of administration: Intravenous
FDA approval date: February 14, 2014
Classification: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) ( 1 ).
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances